Emmanuel Antonarakis

Professor

School of Medicine

If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Dive into the research topics where Emmanuel Antonarakis is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

14 Similar Profiles

Prostatic Neoplasms Medicine & Life Sciences

Castration Medicine & Life Sciences

docetaxel Medicine & Life Sciences

Androgen Receptors Medicine & Life Sciences

Androgens Medicine & Life Sciences

Therapeutics Medicine & Life Sciences

Prostate-Specific Antigen Medicine & Life Sciences

Circulating Neoplastic Cells Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 2002 2019

192 Article
15 Review article
9 Editorial
6 Comment/debate
6 More

Androgen Receptor Modulation Optimized for Response—Splice Variant: A Phase 3, Randomized Trial of Galeterone Versus Enzalutamide in Androgen Receptor Splice Variant-7–expressing Metastatic Castration-resistant Prostate Cancer

Taplin, M. E., Antonarakis, E. S., Ferrante, K. J., Horgan, K., Blumenstein, B., Saad, F., Luo, J. & de Bono, J. S., Dec 2019, In : European Urology. 76, 6, p. 843-851 9 p.

Research output: Contribution to journal › Article

Castration

Androgen Receptors

Prostatic Neoplasms

Circulating Neoplastic Cells

3-hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene

A New Molecular Taxonomy to Predict Immune Checkpoint Inhibitor Sensitivity in Prostate Cancer

Antonarakis, E., Jan 1 2019, (Accepted/In press) In : Oncologist.

Research output: Contribution to journal › Article

Prostatic Neoplasms

A phase II randomized placebo-controlled double-blind study of salvage radiation therapy plus placebo versus SRT plus enzalutamide with high-risk PSA-recurrent prostate cancer after radical prostatectomy (SALV-ENZA)

Kapoor, R., Deek, M. P., McIntyre, R., Raman, N., Kummerlowe, M., Chen, I., Gaver, M., Wang, H., Denmeade, S., Lotan, T., Paller, C., Markowski, M., Carducci, M., Eisenberger, M., Beer, T. M., Song, D. Y., Deweese, T. L., Hearn, J. W., Greco, S., Deville, C. & 7 others, Desai, N. B., Heath, E. I., Liauw, S., Spratt, D. E., Hung, A. Y., Antonarakis, E. S. & Tran, P. T., Jun 13 2019, In : BMC cancer. 19, 1, 572.

Research output: Contribution to journal › Article

Open Access

Salvage Therapy

Prostatectomy

Double-Blind Method

Prostatic Neoplasms

Radiotherapy

A phase I study of the antibody drug conjugate ASG-5ME, an SLC44A4-targeting antibody carrying auristatin E, in metastatic castration-resistant prostate cancer

McHugh, D., Eisenberger, M., Heath, E. I., Bruce, J., Danila, D. C., Rathkopf, D. E., Feldman, J., Slovin, S. F., Anand, B., Chu, R., Lackey, J., Reyno, L., Antonarakis, E. & Morris, M. J., Jan 1 2019, In : Investigational New Drugs.

Research output: Contribution to journal › Article

Castration

Prostatic Neoplasms

Maximum Tolerated Dose

Antibodies

Fatigue

A pilot study of prostate-specific membrane antigen (PSMA) dynamics in men undergoing treatment for advanced prostate cancer

Paller, C., Piana, D., Eshleman, J., Riel, S., Denmeade, S. R., Isaacsson Velho, P., Rowe, S., Pomper, M. G., Antonarakis, E., Luo, J. & Eisenberger, M., Jan 1 2019, In : Prostate. 79, 14, p. 1597-1603 7 p.

Research output: Contribution to journal › Article

Prostatic Neoplasms

Circulating Neoplastic Cells

Therapeutics

Castration

Prostate-Specific Antigen